United States (PRWEB) December 11, 2014
Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiry of several leading drugs, according to a latest report from Reportstack, the largest online library of market research reports. The company’s report on Global Pharmaceutical Market Benchmark Report - Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca (AZ), with a significant proportion of losses coming in the Central Nervous System (CNS) treatment sector.
Complete report can be found by visiting Global Pharmaceutical Market Benchmark Report.
Adam Dion, MS, a GlobalData analyst covering Healthcare Industry Dynamics, states that Eli Lilly and AZ have seen profits fall in the CNS therapeutics market since 2010, with the latter losing the greatest share over the past three years.
Dion comments: “AZ’s CNS segment has been bleeding sales as a result of the company losing its patent on Seroquel (quetiapine fumarate), a treatment for bipolar disorder, which led to the entry of cheaper generic alternatives from Teva and Sandoz. The report estimates AZ’s share to have been around 9% in 2010, which has now fallen to only 3% in 2013.
“Eli Lilly’s market share declined from 14.3% in 2010 to 11.2% in 2013, primarily thanks to decreasing sales of Zyprexa (olanzapine), the company’s dopamine antagonist used to treat schizophrenia and bipolar disorder. Zyprexa sales have plummeted from over $5 billion to $1.2 billion over the same period, as a result of the drug losing its US patent exclusivity in 2011.”
The analyst adds that while Otsuka’s anti-psychotic drug Abilify (aripiprazole), which the company co-markets with Bristol-Myers Squibb, was the sales leader in the CNS arena with $9.5 billion in 2013, the drug faces a less positive future.
Dion explains: “Otsuka benefited from higher annual sales across most major markets in 2013 due to reimbursement and label expansions. In the US and Europe, prescriptions increased for adjunctive therapy in major depressive disorder and manic episodes of bipolar disorder, while there were rising sales in China, where the drug was included in the national medical insurance system.
“However, Abilify’s upcoming US patent expiration in 2015 means the drug will lose a massive $6.2 billion by 2019 as the result of generic competition, making it the biggest victim of the pharmaceutical industry’s current patent cliff.”
What are the key questions answered in this report?
- What specific strategies are these drug companies employing to gain market share?
- What drivers accounted for the revenue growth for the company over the past year?
- Which trends will affect the global pharmaceutical market over the next few years?
- Who are the revenue and growth leaders in each therapeutic and geographical area?
- What specific business development activities are taking place, in terms of partnerships or M&A?
- What are the top-selling drugs in each therapeutic franchise and what are their sales forecasts through 2019?
Other Pharma Market Research Reports from Reportstack:
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries
Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 – Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat
About Reportstack:
Reportstack is one of the leading distributors of market research reports in the world today. Reportstack provides access to over 50,000 company profiles and their strategic information like SWOT analysis, pharma pipeline review reports, chemical industry reports, deals and partnerships analysis, merger & acquisition activity and new product launches. Reportstack is also a leader in the field of consumer retail research, pharma and healthcare market research reports.
Contact:
Nathan Gold
Email: nathan(at)reportstack(dot)com
Reportstack Market Research
Ph: +1-888-789-6604
United States